



PDRadiopharma Inc.

**PeptiDream Announces Upcoming Presentations, and
PDRadiopharma to Exhibit at the 64th Annual Scientific Meeting of
the Japanese Society of Nuclear Medicine and the 44th Annual
Meeting of the Japanese Society of Nuclear Medicine Technology**

TOKYO, JAPAN – November 6, 2024 – PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo: 4587) announced that the company and PDRadiopharma Inc. (President and CEO: Masato Murakami, Headquarters: Chuo-ku, Tokyo, Japan, “PDRadiopharma”) will be presenting PD-32766 program targeting Carbonic Anhydrase IX (“CA9”) as a potential targeted radiotherapy and radiodiagnostic for clear cell renal cell carcinoma (“ccRCC”) at the 64nd Annual Scientific Meeting of the Japanese Society of Nuclear Medicine (JSNM) and Current status of nuclear medicine imaging in the reimbursement system based on DPC/PDPS at the 44nd Annual Meeting of the Japanese Society of Nuclear Medicine Technology (JSNMT) held on November 7-9, 2024. Furthermore, PDRadiopharma will set up an exhibition booth for medical devices and other products during the duration of this conference.

【Information on the presentation】

The 64nd Annual Scientific Meeting of the Japanese Society of Nuclear Medicine and the 44nd Annual Meeting of the Japanese Society of Nuclear Medicine Technology (November 7-9, 2024)
Location: Yokohama, Kanagawa Prefecture

Title: A novel CA9-binding peptide, PD-32766, as a radiotheranostics drug for renal cell cancer

Presentation Format: Oral (1-MO03-6)

Date: 10:40-11:40am November 7, 2024 (JT)

Title: Current status of nuclear medicine imaging in the reimbursement system based on DPC/PDPS

Presentation Format: JSNMT Symposium

Date: 3:30-5:30pm November 8, 2024 (JT)

【Information on the exhibitor booth】

PDRadiopharma is set to exhibit a comprehensive range of its products at its exhibition booth. Highlights include our DX solutions such as "onti," which supports nuclear medicine operations and ensures medical safety, and the actual AMYclz® Neuro, certified as a "managed medical device" on October 22, 2024. Attendees will have the opportunity for hands-on interaction with these products.

Booth location: No. 20

Date: 9:30am - 5:00pm November 7, 2024 (JT)

9:00am -5:00pm November 8, 2024 (JT)

9:00am -12:00pm November 9, 2024 (JT)

About PDRadiopharma

PDRadiopharma, a wholly-owned subsidiary of PeptiDream from 2022, has been providing high-quality radiopharmaceuticals through the research and development, manufacturing, regulatory and sales as a forerunner in the field of radiopharmaceuticals, since it started its business in 1968. Currently PDRadiopharma offers 21 radiodiagnostic products (spanning both SPECT and PET products) and 8 radiotherapeutic products (3 product categories) in Japan. Additionally, PDRadiopharma and PeptiDream are developing a broad pipeline of radiotherapeutics and radiodiagnostics for both the Japan and global markets. For more information about PDRadiopharma, please visit www.pdradiopharma.com.

Inquiries:

PDRadiopharma Inc.

Contact: Noriko Tanaka, General Affairs

Email: s-info-hq@pdradiopharma.com